Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Alessandra Nerviani et al.|The Lancet|2021Cited by 315
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)Jatin Patel, Mark Layton, Damon Bass et al.|European Respiratory Journal|2022Cited by 42
A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)Jatin Patel, Mark Layton, Albertus Beishuizen et al.|medRxiv|2021Cited by 27